Overview of Mapa

What is Mapa? Defining the Combination Analgesic Entity

Property	Description
Active Ingredients	Paracetamol (Acetaminophen) and Tramadol Hydrochloride
Form	Oral Solid Preparation (FDC Tablet)
Pharmacological Class	Combination Analgesic
Common Use	Pain relief
Origin	Synthetic

Mapa is a prescription-only medication classified as a Combination Analgesic, identified with the anatomical therapeutic chemical (ATC) code N02AJ13. It is a synthetic compound manufactured as an Oral Solid Preparation, specifically a Fixed-Dose Combination (FDC) Tablet. The formulation integrates two distinct active ingredients: Paracetamol (Acetaminophen), a widely used simple analgesic, and Tramadol Hydrochloride, a centrally-acting opioid analgesic. This specific combination is widely recognized and marketed internationally under various trade names, underscoring its established clinical use.

The inclusion of two different agents means the drug is fundamentally dual-action, distinguishing it from single-agent preparations. This FDC format ensures that both components are delivered simultaneously via the Oral Route of Administration. Furthermore, the combined approach means the pharmacological effect of the two agents is designed to be synergistic, providing complementary mechanisms of pain relief. This combination is recognized for its application in various pain conditions.

Composition and The Principle of Dual Action

The composition of Mapa is based on the combined action of Paracetamol and Tramadol Hydrochloride to achieve a multi-modal and synergistic analgesic effect; this means the combined therapeutic output of the two ingredients is greater than the sum of their individual effects if administered separately. This synergy is purposeful, relying on the distinct ways each component addresses pain.

Paracetamol, the non-opioid component, acts to modulate the creation of pain signals in the central nervous system (CNS), while Tramadol works through engaging mu-opioid receptors and modulating inhibitory neurotransmitters to lessen the perception and transmission of those pain signals. This dual pathway is why the combination is frequently utilized in pain management protocols where single-agent analgesics may be insufficient. The general therapeutic purpose of this dual-action combination is, therefore, to provide more comprehensive pain relief through multiple pathways than is possible with either component alone.

Therapeutic Uses of Mapa

What Mapa treats: main uses and benefits

Mapa is a combination analgesic commonly used for symptomatic pain relief in situations where the discomfort is significant enough to require a dual-action approach. Its use is generally focused on symptoms severe enough that alternative treatments may be considered inadequate.

This medication is applied in situations involving moderate to moderately severe pain intensity that is not adequately managed by simple, non-opioid treatments. It helps address symptom clusters that may appear suddenly or intensify over time, contributing to providing symptomatic support and may assist patients with coping during difficult episodes.

Common Symptomatic Uses

Mapa is relevant in clinical settings marked by increased discomfort and tension, specifically used to help manage pain associated with: postoperative recovery, musculoskeletal conditions like osteoarthritis, chronic lower back pain, and managing symptoms in complex states such as painful diabetic peripheral neuropathy.

“Applied across domains where additional symptomatic support is needed, the medication plays a role in managing symptoms that helps ease the overall symptom burden during symptomatic periods.”

Quick Fact: This combination is primarily relevant for episodes of moderate to moderately severe pain where a dual-action approach is appropriate, providing supportive relief when symptoms interfere with routine activities.

Regulatory References

DailyMed: Tramadol Hydrochloride and Acetaminophen Tablets

Eligibility and Restrictions for Use

Official Eligibility Rules for Mapa Use

Mapa (Tramadol and Paracetamol) is a prescription-only medication whose use is strictly governed by regulatory eligibility criteria established by authorities like the FDA and EMA. These rules define who is permitted to use the medicine and who must not, based primarily on the risks associated with the tramadol component and the hepatotoxicity potential of paracetamol.

Contraindicated Populations

Use of Mapa is absolutely contraindicated in several populations. This includes all children younger than 12 years of age, and those younger than 18 years following tonsillectomy or adenoidectomy. The medicine must not be used in patients with severe hepatic (liver) impairment, significant respiratory depression, or who are acutely intoxicated with alcohol, opioids, or hypnotic drugs. Use is also prohibited for patients currently taking Monoamine Oxidase Inhibitors (MAOIs) or within two weeks of stopping them.

Restricted and Conditional Use

Use is not recommended for patients with severe renal (kidney) or severe respiratory insufficiency. Special consideration and caution are required for adults over 75 years of age, where the interval between doses may need adjustment. Furthermore, regulatory agencies advise that the medicine is not recommended for use by women who are pregnant or breastfeeding due to documented risks, including the potential for Neonatal Opioid Withdrawal Syndrome (NOWS).

What should I know about interactions with other medicines?

Mapa Interactions with other medicines and products

The substance referred to as Mapa (Methyl alpha-phenylacetoacetate) is not a registered pharmaceutical drug product and therefore does not have standard drug labeling information regarding drug-drug, drug-food, or drug-herb interactions. It is not intended for use in humans for the treatment of any medical condition.

Mapa's regulatory status is determined by its classification as a List I chemical under the U.S. Controlled Substances Act (CSA) and its inclusion in Table I of the 1988 United Nations Convention. This classification is based solely on its use as a chemical precursor in the illicit manufacture of controlled substances, specifically the Schedule II substances methamphetamine and amphetamine, via the intermediate phenylacetone (P2P).

Interaction-Related Regulatory Context

Regulatory Classification	Contextual Constraint
Interacting Substances	None (Not a finished medicinal product)
Official Restriction	Listed I chemical subject to DEA chemical control regulations
Mechanistic Basis	Chemical conversion/synthesis to a controlled drug
Clinical Interaction Notes	None (No documented therapeutic use)

This regulatory control imposes restrictions on the chemical's handling, including its manufacture, distribution, import, and export. There are no clinical interaction statements, such as contraindicated combinations, pharmacokinetic interactions, or spacing requirements, associated with its use.

Mechanism of Action

Mapa operates via three separate biological mechanisms exclusively within the central nervous system (CNS). This multi-modal approach targets distinct checkpoints in the nociceptive system.

Multi-Modal Central Impulse Inhibition

The Tramadol component acts on two separate systems to inhibit the transmission of nociceptive impulses. Its active metabolite, M1, functions as an agonist at the mu-Opioid Receptors ( MOR), leading to the hyperpolarization of nociceptive neurons and contributes to the dampening of nociceptive impulse propagation in the spinal cord and brain. Concurrently, the parent drug blocks the reuptake of the neurotransmitters Serotonin ( SERT) and Norepinephrine ( NET), thereby augmenting the CNS's descending inhibitory pathways to suppress the transmission of nociceptive impulses.

Modulation of the Nociceptive Threshold

The Paracetamol component contributes by modulating the central nociceptive threshold. It functions as an inhibitor of Cyclooxygenase (COX) enzymes, primarily within the CNS, which sharply reduces the synthesis of pro-nociceptive prostaglandins that sensitize pain pathways. This central mechanism increases the physiological threshold required for a signal to register, thereby reducing the central sensitivity to noxious stimuli.

Synergistic Targeting and Mechanistic Limitation

The combination of Paracetamol's central threshold elevation and Tramadol's dual-action transmission blockade results in a synergistic effect, enabling multi-target physiological modulation of the nociceptive cascade. However, the mu-opioid mechanism is reliant on the CYP2D6 enzyme for activation; consequently, individuals with low CYP2D6 activity will experience a significantly diminished MOR effect.

Dosage and Administration Information

Official Administration Protocol

Mapa is an oral fixed-dose combination tablet containing Tramadol 37.5 mg and Paracetamol 325 mg. Administration follows established parameters regarding dosing, frequency, and duration.

Instruction	Guideline
Route of Administration	Oral. Tablets must be swallowed whole with liquid and should not be broken, chewed, or crushed.
Initial/Maintenance Dose	An initial dose of two tablets (Tramadol 75 mg / Paracetamol 650 mg) is recommended.
Maximum Daily Dose	The dose must not exceed eight tablets per day (Tramadol 300 mg / Paracetamol 2600 mg).
Dosing Interval	The minimum interval between doses is six hours. May be taken with or without food.
Duration of Use	Use should be limited to the shortest duration strictly necessary, often defined as five days or less for acute pain.
Co-administration	The medicine must not be used concurrently with any other product containing Paracetamol (Acetaminophen) or Tramadol.

Population-Specific Adjustments

Specific dose interval modifications exist for certain patient populations:

Renal Impairment (creatinine clearance <30 mL/min): The dosing interval should be extended to 12 hours, and the maximum daily dose must not exceed two tablets every 12 hours.
Severe Hepatic Impairment: The use of this combination is not recommended.
Children: Use is not recommended for children under 12 years of age.

These standardized instructions define the procedural structure for administering the medicine, establishing limits on both the amount and frequency of intake.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Mapa (Tramadol/Paracetamol FDC)

Evidence for Use in Acute Pain (Post-Operative and Dental)

Research examined the combination in the context of acute discomfort, such as pain that comes on suddenly after surgery or a dental procedure. The evidence is derived mostly from short-term, randomized controlled trials (RCTs). These studies were applied in research contexts involving fluctuating or unstable symptoms in adult populations who were experiencing outcomes related to physical discomfort. The primary research examined how symptoms change over time and the need for supplemental analgesic medication.

In these trials, findings describe patterns observed in the studies where the combination was monitored for changes in pain intensity scores during the immediate follow-up period. Research focusing on episodes where symptoms become more noticeable tracked outcomes related to patient-reported perceived discomfort shortly after administration. Research exploring short-term symptom changes does not provide data on the treatment's role in extended post-operative recovery. What remains uncertain is how patterns observed in the research apply to symptoms that persist for a longer duration or pain lasting longer than 10 days.

Evidence for Use in Chronic Musculoskeletal Conditions

Research has also explored the combination analgesic in conditions marked by functional limitations and persistent discomfort, such as in chronic musculoskeletal issues. The evidence base here relies on intermediate-term RCTs that monitored populations over defined time intervals, usually for several weeks.

Evidence for Osteoarthritis Pain

The combination was studied for the symptomatic management of Osteoarthritis (OA). Studies monitored outcomes reflecting daily functioning or activity level, such as the WOMAC scales, used in adult populations with moderate to moderately severe OA. Trials described measurements of pain intensity and functional status changes over follow-up periods ranging from 4 to 12 weeks. While research provides insight into short-term changes, comparative evidence is lacking against all other active treatments. The research attributes measured consistency of evidence as moderate, and there is limited information for long-term outcomes.

Evidence for Chronic Lower Back Pain

Research explored the combination in adult populations experiencing persistent Chronic Lower Back Pain (CLBP). Studies explored outcomes reflecting daily functioning or activity level, such as improvement in measures of functional disability. Studies report how symptoms were monitored in the observed populations, with data showing patterns related to outcomes describing perceived discomfort and functional measures over the intermediate term. However, evidence quality varies across studies, and long-term effects are not fully established for this chronic condition.

Frequently Asked Questions (FAQ)

Common questions about Mapa (FAQ)

Q: What are the most commonly reported side effects when first starting Mapa?

According to the official product information, certain effects are classified as Very Common, occurring in more than 1 in 10 users. These frequently reported reactions include nausea, dizziness, and somnolence (drowsiness). Safety notes also indicate that the risk for serious effects like respiratory depression is highest when treatment is initiated or when the dose is increased.

Q: Is it considered a normal experience to feel mild [common symptom] after taking Mapa?

Official regulatory documents list several reactions based on how often they occur in studies. Symptoms like nausea, dizziness, and drowsiness are classified as Very Common. Other common reactions, observed in up to 1 in 100 users, include vomiting, constipation, headache, and dry mouth.

Q: Can Mapa be used by women who are pregnant or planning to conceive?

Official regulatory bodies state that the medicine is not recommended for women who are pregnant or are breastfeeding. This advisory is due to documented risks to the child, which include the potential for Neonatal Opioid Withdrawal Syndrome.

Q: Is there a best time of day (morning or night) to take Mapa?

The medication may be taken with or without food. Since official documents list drowsiness (somnolence) and dizziness as Very Common adverse reactions, some users may find it beneficial to consider these potential effects when deciding the time of day to administer the dose.

Q: What is the total length of time most people are prescribed Mapa?

Official guidelines limit the duration of use to the shortest period strictly necessary, often defined as five days or less for acute, sudden pain. Regulatory research has also examined the combination for intermediate periods, ranging from four to twelve weeks, for managing persistent chronic conditions like Osteoarthritis, but the official duration limit remains the shortest duration strictly necessary.

Q: Why is Mapa categorized as a prescription-only medicine?

Mapa is categorized as a prescription-only, Schedule IV controlled substance due to the presence of the tramadol component. This classification is required because of the documented risk of developing Opioid Use Disorder (abuse and misuse), which necessitates professional medical supervision and monitoring.

Q: Can Mapa be taken at the same time as my other routine prescription medicines?

The medicine is strictly contraindicated (prohibited) for patients taking Monoamine Oxidase Inhibitors (MAOIs) or within two weeks of stopping them. Due to potential safety concerns, official warnings also restrict concomitant use with other Central Nervous System (CNS) Depressants.

Q: Are there any specific foods or supplements I should avoid while taking Mapa?

The medicine is generally permitted to be taken with or without food. However, official documents strictly state that the medicine is contraindicated if a person is acutely intoxicated with alcohol, and it must not be used concurrently with any other medicine containing paracetamol or tramadol.

Q: Can Mapa affect sleep patterns?

Studies and official product information indicate that the medicine can affect the central nervous system. Drowsiness (somnolence) is listed as a Very Common adverse reaction, and the tramadol component has been shown in research to potentially alter sleep structure, such as decreasing the duration of REM sleep.

Q: Does Mapa have a known risk of causing dependence?

Yes, the official labeling recognizes the risk of physical dependence and the potential for developing Opioid Use Disorder (addiction, abuse, and misuse). Physical dependence means that stopping the medicine abruptly can lead to a withdrawal syndrome.

Q: Is the active ingredient of Mapa known to pass into breast milk?

Regulatory agencies advise that the medicine is not recommended for use by women who are breastfeeding. This is due to documented risks, including the active ingredient's known passage into breast milk and the potential for Neonatal Opioid Withdrawal Syndrome.

Q: Does the official research on Mapa include long-term outcome data?

Research evidence primarily covers short-term and intermediate-term randomized controlled trials, typically up to 12 weeks. Official documents explicitly state that the evidence for long-term effects for chronic conditions is limited and that long-term outcomes are not fully established.

Q: Does a generic version of Mapa currently available to the public?

Mapa is one of many brand names for this combination product. Its active ingredients, Paracetamol and Tramadol Hydrochloride, are widely available as generics and in various other combination products internationally.

Q: What should be expected when stopping Mapa after a long period of use?

Official warnings state that stopping the use of this medicine abruptly, especially after a long period, can result in a withdrawal syndrome. This may include both typical opioid withdrawal symptoms and an atypical withdrawal syndrome due to the Tramadol component's dual action.

Q: Are there any common activities, like driving, that are affected by taking Mapa?

Yes, due to its action on the central nervous system, Very Common side effects include dizziness and somnolence (drowsiness). These documented effects may impair mental and physical abilities required to perform common activities, such as driving a car or operating machinery.

Q: Does the effectiveness of Mapa change with prolonged use?

Regulatory documents recognize the risk of developing tolerance with the prolonged use of the medicine. Tolerance development implies that the body may adapt to the medicine over time, which could potentially reduce its effectiveness.

Q: Is it known if Mapa affects laboratory test results?

The official safety profile notes that an increase in hepatic transaminases (liver enzymes) is classified as an Uncommon adverse reaction. These enzymes are measurable laboratory test results, meaning the medicine can affect liver function markers.

Q: What are the common effects of Mapa on mood or emotional state?

Official warnings indicate that the medicine has effects on the central nervous system and is associated with risks such as Serotonin Syndrome. While depression is listed as an Uncommon side effect, the labeling also carries warnings regarding the risk of suicide and should be considered in context of its effect on neurotransmitters.

How should Mapa be stored and disposed of?

How to Store and Dispose of Mapa?

Mapa (Tramadol/Paracetamol) must be stored according to official regulatory specifications to maintain stability and prevent accidental access.

Storage Requirements

The tablets require storage at controlled room temperature, typically 20 C to 25 C (68 F to 77 F), and must be protected from freezing, excessive heat, moisture, and direct light. It is a mandatory requirement that this opioid-containing medicine be kept out of the sight and reach of children and maintained in a closed container.

Disposal Instructions

Unused or expired tablets should be disposed of immediately via a drug take-back program or mail-back envelope, as this is the preferred method for controlled substances. If no take-back option is available, the official alternative is to mix the medicine with an undesirable substance (like coffee grounds or dirt) in a sealed bag before discarding it in the household trash. Disposal must always adhere to local environmental and pharmaceutical waste regulations.

Overdose Presentation and Scope	Regulatory Documentation Summary
Documented Manifestations	Symptoms include signs of opioid toxicity (e.g., severe respiratory depression, miosis, somnolence, seizures, coma) and signs of Paracetamol toxicity (e.g., pallor, nausea, vomiting, abdominal pain).
Severe Outcomes	Life-threatening risks include hepatic necrosis and fatal liver failure (potentially delayed by up to 48 hours), cardiac arrest, circulatory collapse, and respiratory arrest.
Population Note	Patients with pre-existing hepatic or renal impairment and those with respiratory diseases face an increased risk of severe toxicity and respiratory compromise.

Emergency Action and Management Focus	Regulatory Documentation Summary
Immediate Action Required	Seek immediate medical attention or contact a Poison Control Center immediately upon any suspected overdose, regardless of whether symptoms are currently present.
Antidote Availability	The official management protocol specifies the use of Naloxone to reverse Tramadol-induced respiratory depression and N-acetylcysteine (NAC) for Paracetamol toxicity.

Mapa